Combating Illicit Xylazine Act
- Bill Number
- H.R. 1266
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Crime and Law Enforcement
- Status
- Introduced
- Latest Action
- 2026-06-25: Forwarded by Subcommittee to Full Committee by Voice Vote.
- Last Updated
- 2026-07-01T08:08:21Z
AI-Generated Summary
Purpose of the Legislation
The "Combating Illicit Xylazine Act" (H.R. 1266) aims to address the growing illicit use of xylazine—a veterinary sedative often mixed with opioids—by classifying it as a controlled substance under federal law. This helps curb its diversion for non-medical human use, such as in the illegal drug trade, while preserving legitimate veterinary applications.
Key Provisions
- Definition and Scheduling: Defines "xylazine" (including its salts, isomers, and related forms) in the Controlled Substances Act (CSA) and adds it to Schedule III. Schedule III substances have accepted medical uses but a moderate potential for abuse and dependence; they require prescriptions and are subject to strict handling rules.
- Ultimate User Definition: Updates the CSA's definition of an "ultimate user" (the final lawful possessor of a controlled substance) specifically for xylazine. This allows possession without registration for:
- Animals owned by the user or their household.
- Animals under the user's care.
- Government animal-control or wildlife programs authorized by law.
- Dispensing must come from registered veterinarians or pharmacies via veterinary prescriptions. "Ultimate users" include government agencies, businesses with animals, and their employees acting in official roles.
- Exemptions and Transition Periods:
- Existing xylazine manufacturers are not required to install new security measures (like safes or alarms) for Schedule III compliance.
- Labeling, packaging, and distribution rules for xylazine take effect 1 year after enactment.
- Practitioner registration, inventory, and recordkeeping requirements start 60 days after enactment; practitioners applying during this window can continue operations until approval or denial.
- The FDA and DEA must expedite manufacturer applications related to the scheduling.
- Ultimate users of xylazine for allowed purposes do not need to register under the CSA.
- Tracking and Reporting:
- Requires xylazine to be tracked via the DEA's Automated Reports and Consolidated Orders System (ARCOS), a database for monitoring controlled substance distribution (similar to rules for certain other drugs).
- Directs the U.S. Sentencing Commission to review and update federal sentencing guidelines for crimes involving xylazine under the CSA, ensuring penalties match its risks, especially when mixed with other drugs.
- Mandates two reports to Congress from the DEA (in coordination with the FDA):
- An initial report within 18 months on illicit xylazine use, diversion sources, origins, and potential analogues (similar substances) posing abuse risks.
- An update within 4 years on trafficking and misuse trends.
Significant Changes to Existing Law
- New Classification: This is the first time xylazine is explicitly defined and placed in Schedule III of the CSA, treating it like other non-narcotic drugs with abuse potential (e.g., certain steroids or ketamine). Previously, xylazine was unregulated federally as a human drug but used in veterinary medicine.
- Tailored User Rules: Narrows the general "ultimate user" definition for xylazine to protect veterinary and animal care access, unlike broader rules for other Schedule III substances that might require more restrictions.
- Delayed Implementation: Introduces grace periods for compliance, which are not standard for all CSA amendments, to ease the burden on the veterinary and manufacturing sectors.
- Enhanced Oversight: Adds xylazine to ARCOS tracking and sentencing reviews, aligning it with monitoring for drugs like gamma hydroxybutyric acid (GHB), but without immediate full security mandates for manufacturers.
Potential Impacts
- On Government Agencies: The DEA will gain authority to regulate, track, and prosecute xylazine-related offenses, increasing enforcement workload but providing tools to combat the opioid crisis (xylazine is often laced with fentanyl). The FDA will assist with product approvals and transitions. Congress will receive data-driven reports to inform future policy.
- On Citizens: Limits illicit access, potentially reducing overdose risks from xylazine's sedative effects (which can cause severe wounds and respiratory failure when misused). Legitimate users, like pet owners or farmers, face minimal disruption due to exemptions, but veterinarians must adapt to new registration timelines.
- On International Relations: Could affect imports of xylazine (often sourced from abroad) by enabling DEA scrutiny of international trafficking, potentially leading to diplomatic efforts with supplier countries to curb diversions. No direct impact on trade agreements, but it strengthens U.S. drug control under international treaties like the UN Convention on Psychotropic Substances.
Main Stakeholders Affected
- Federal Agencies: DEA (enforcement and reporting), FDA (approvals and coordination), and U.S. Sentencing Commission (guideline updates).
- Veterinarians and Pharmacies: Must register and follow new rules for prescribing/dispensing xylazine, with a 60-day grace period.
- Animal Owners and Businesses: Farmers, pet owners, zoos, government animal control programs, and wildlife agencies benefit from clarified lawful possession without registration.
- Manufacturers: Existing producers avoid costly security upgrades but must submit expedited applications; new entrants face full Schedule III requirements.
- Illicit Users and Traffickers: Face heightened penalties and tracking, targeting the street drug supply where xylazine is mixed with opioids.
- Public Health Community: Researchers, harm reduction groups, and medical professionals may see indirect benefits from reduced misuse, though reports could highlight emerging risks from analogues.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens federal prosecution tools under the CSA for xylazine offenses (e.g., distribution penalties up to 5–20 years imprisonment for Schedule III violations, depending on quantity). The tailored exemptions prevent overreach into veterinary practice, but courts may need to interpret "ultimate user" boundaries in possession cases.
- Constitutional: Relies on Congress's commerce clause authority to regulate interstate drug distribution, consistent with prior CSA rulings (e.g., Gonzales v. Raich). No apparent free speech or due process issues, as it targets conduct rather than expression.
- Political: Bipartisan sponsorship (from 30+ members across parties) reflects consensus on addressing the fentanyl crisis's evolution, without restricting legitimate animal health uses. It avoids full bans to balance public safety with agriculture/veterinary needs, potentially setting a model for scheduling emerging drug threats.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (111)
Rep. Pfluger, August [R-TX-11], Rep. Bilirakis, Gus M. [R-FL-12], Rep. Pappas, Chris [D-NH-1], Rep. Fitzgerald, Scott [R-WI-5], Rep. Ross, Deborah K. [D-NC-2], Rep. Crenshaw, Dan [R-TX-2], Rep. Harder, Josh [D-CA-9], Rep. DelBene, Suzan K. [D-WA-1], Rep. Miller-Meeks, Mariannette [R-IA-1], Rep. Pettersen, Brittany [D-CO-7], Rep. Clarke, Yvette D. [D-NY-9], Rep. Deluzio, Christopher R. [D-PA-17], Rep. Magaziner, Seth [D-RI-2], Rep. Bacon, Don [R-NE-2], Rep. Obernolte, Jay [R-CA-23], Rep. Costa, Jim [D-CA-21], Rep. Balderson, Troy [R-OH-12], Rep. Barragán, Nanette Diaz [D-CA-44], Rep. Ciscomani, Juan [R-AZ-6], Rep. Carey, Mike [R-OH-15], Rep. Bice, Stephanie I. [R-OK-5], Rep. Craig, Angie [D-MN-2], Rep. Norcross, Donald [D-NJ-1], Rep. Fong, Vince [R-CA-20], Rep. Tenney, Claudia [R-NY-24], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Burchett, Tim [R-TN-2], Rep. Dean, Madeleine [D-PA-4], Rep. Cohen, Steve [D-TN-9], Rep. Davis, Donald G. [D-NC-1], Rep. Correa, J. Luis [D-CA-46], Rep. Webster, Daniel [R-FL-11], Rep. Collins, Mike [R-GA-10], Rep. Suozzi, Thomas R. [D-NY-3], Rep. Harshbarger, Diana [R-TN-1], Rep. Salinas, Andrea [D-OR-6], Rep. Lee, Laurel M. [R-FL-15], Rep. Wittman, Robert J. [R-VA-1], Rep. Mann, Tracey [R-KS-1], Rep. Soto, Darren [D-FL-9], Rep. Cherfilus-McCormick, Sheila [D-FL-20], Rep. Haridopolos, Mike [R-FL-8], Rep. Sewell, Terri A. [D-AL-7], Rep. Rulli, Michael A. [R-OH-6], Rep. Finstad, Brad [R-MN-1], Rep. Davids, Sharice [D-KS-3], Rep. Yakym, Rudy [R-IN-2], Rep. Self, Keith [R-TX-3], Rep. Harris, Andy [R-MD-1], Rep. Calvert, Ken [R-CA-41] and 61 more
Recent Actions
- 2026-06-25: Forwarded by Subcommittee to Full Committee by Voice Vote.
- 2026-06-25: Subcommittee Consideration and Mark-up Session Held
- 2025-02-12: Referred to the Subcommittee on Health.
- 2025-02-12: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-12: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-12: Introduced in House
- 2025-02-12: Introduced in House
Bill Versions
- Combating Illicit Xylazine Act — issued 2025-02-12 — PDF (7 pages)